CSV February 22, 2023 through February 22, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MESO-	COMPOSITION	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	In *System*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ZEAXANTHIN	/*Stereoisomeric Composition*							*suitability*: Change [Note—The approximate relative retention times for (3*S*,3?*S*)-zeaxanthin, (3*R*,3?*S*-*meso*)-zeaxanthin, (3*R*,3?*R*)-zeaxanthin, and (3*R*,3?*R*,6?*R*)-lutein are 0.94, 1.00, 1.06, and 1.11, respectively.] to: [Note—The approximate relative retention times for (3*S*,3?*S*)-zeaxanthin, (3*R*,3?*S*)-zeaxanthin, (3*R*,3?*R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-zeaxanthin, and (3*R*,3?*R*,6?*R*)-lutein are 0.94, 1.00, 1.06, and 1.11, respectively.] AND In *System suitability/Suitability requirements/Resolution*: Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Analysis*: Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND In *Acceptance criteria*: Change (3*R*,3?*S*-*meso*)-Zeaxanthin to: (3*R*,3?*S*)-Zeaxanthin
POTASSIUM GLUCONATE ORAL SOLUTION	SPECIFIC TESTS	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	Change **Alcohol Determination** ?611?, *Method II—Distillation Method*: to: **Alcohol Determination** ?611?, *Method I—Distillation Method*:
Methyl Acetate	CHEMICAL INFORMATION	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	Change CAS RN®: 74-20-9. to: CAS RN®: 79-20-9.
MESO-ZEAXANTHIN	CHEMICAL INFORMATION	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	Change (3*R*,3?*S*-*meso*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AZTEC MARIGOLD ZEAXANTHIN EXTRACT	COMPOSITION /*Procedure 4: Stereoisomeric Composition*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	)-Zeaxanthin to: (3*R*,3?*S*)-Zeaxanthin In *System suitability*/*Suitability requirements*/*Resolution*: Change (3*R*,3?*S* *meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Analysis*: Change (3*R*,3?*S* *meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Acceptance criteria*: Change (3*R*,3?*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								meso)-Zeaxanthin to: (3*R*,3?*S*)-Zeaxanthin
ISOBUTYL ALCOHOL	ASSAY/ *Procedure*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Analysis*: Change r_S = sum of all the peaks except those each of which with an area less than 0.1 times the area of the major peak from the *Reference solution* to: r_T = sum of all the peaks except those each of which with an area less than 0.1 times the area of the major peak from the *Reference solution*
FLUTICASONE IM		*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PROPIONATE NASAL SPRAY	PUR ITIES/*Organic Impurities*							Change Samples: *System suitability solution*, *Identification solution*, and *Sample solution* to: Samples: *Identification solution* and *Sample solution*
MESO-ZEAXANTHIN PREPARATION	COMPOSITION /*Stereoisomeric Composition*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *System suitability*: Change [Note—The approximate relative retention times for (3*S*,3?*S*)-zeaxanthin, (3*R*,3?*S*-*meso*)-zeaxanthin, (3*R*,3?*R*)-zeaxanthin, and (3*R*,3?*R*,6?*R*)-lutein are

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								0.94, 1.00, 1.06, and 1.11, respectively.] to: [Note—The approximate relative retention times for (3*S*,3?*S*)-zeaxanthin, (3*R*,3?*S*)-zeaxanthin, (3*R*,3?*R*)-zeaxanthin, and (3*R*,3?*R*,6?*R*)-lutein are 0.94, 1.00, 1.06, and 1.11, respectively.] AND In *System suitabil ity/Suitability re quire ments/ Resolution*: Change (3*R*,3?*S*-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MESO-ZEAXANTHIN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Analysis*: Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Acceptance criteria*: Change (3*R*,3?*S*-*meso*)-Zeaxanthin to: (3*R*,3?*S*)-Zeaxanthin In USP *meso*-Zeaxanthin RS: Change (3*R*,3?*S*-*meso*)-Zeaxanthin. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEAD	PROCEDURES */Procedure 1: Chemical Method*	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	(3*R*,3?*S*)-Zeaxanthin. In *Analysis*: Change Add to the acid solution 5.0 mL of *Standard dithizone solution* and 4 mL of *Ammonia cyanide solution*, to: Add to the acid solution 5.0 mL of *Standard dithizone solution* and 4 mL of *Ammonium cyanide solution*,
METARAMINOL BITARTRATE	SPECIFIC TESTS/*Content of Tartaric Acid*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Analysis*: Change Result = $\{[(V_S?V_B) \times N \times F]/2 \times W\} \times 100$ to: Result = $\{[(V_S?V_B) \times N \times F]/(2 \times W)\} \times$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LYSINE ACETATE	IM PUR ITIES/*Related Compounds*	*USPNF Online*	Online	16-Dec-2022	1-Jun-2023	*NA*	*NA*	100 In *Chromatographic system*/*Spray reagent*: Change 0.2 g of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5) to: 2 mg/mL of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5)
METOLAZONE TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	16-Dec-2022	1-Jan-2023	*NA*	*NA*	In *Buffer*: Change 1.38 g of monobasic potassium phosphate monohydrate in 900 mL of water. to: 1.38 g of monobasic

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sodium phosphate in 900 mL of water.
MAFENIDE ACETATE FOR TOPICAL SOLUTION	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	16-Dec-2022	1-Jan-2023	*NA*	*NA*	In *System suitability*: Change **Samples**: *System suitability solution*, *Standard solution A*, and *Standard solution B* to: **Samples**: *System suitability solution* and *Standard solution A* AND In *Analysis*: Change **Samples**: *Mobile phase*, *Standard solution A*, and *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatograph the *Standard solution* and adjust the integration parameters so that the response is 5%–15% of full-scale deflection. to: **Samples**: *Mobile phase*, *Standard solution A*, *Standard solution B*, and *Sample solution* Chromatograph *Standard solution B* and adjust the integration parameters so that the response is 5%–15% of full-scale deflection.
LYSINE HYDROCHLORIDE	IMPURITIES/*Related*	*USPNF Online*	Online	16-Dec-2022	1-Jun-2023	*NA*	*NA*	In *Chromatographic system*/*Spray*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Compounds							*reagent*: Change 0.2 g of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5) to: 2 mg/mL of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5)
PALONOSETRON HYDROCHLORIDE	IMPURITIES	*USPNF Online*	Online	16-Dec-2022	1-Jan-2023	*NA*	*NA*	In *Limit of Unspecified Impurities*: Change **Mobile phase** and **Chromatographic system**: Proceed as directed in the *Assay*. to: **Mobile phase**, **Standard stock solution**, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatographic system: Proceed as directed in the *Assay*.
ROCURONIUM BROMIDE	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*USPNF 2023 Issue 3*	In footnote b of *Table 1*: Change 2?-(Morpholin-4-yl)-16?-(pyrrolidin-1-yl)-5?-androstan-3?,17?-diol. to: 2?-(Morpholin-4-yl)-16?-(pyrrolidin-1-yl)-5?-androstane-3?,17?-diol.
CHLORHEXIDINE GLUCONATE ORAL RINSE	IMPURITIES/*Limit of p-Chloroaniline*	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	Change **Standard solution**: 1.0 µg/mL of USP *p*-Chloroaniline RS in *Diluent* to: **Standard solution**: 0.001 mg/mL of USP *p*-Chloroaniline

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MOMETASONE FUROATE TOPICAL SOLUTION	IDENTIFICATION	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	RS in *Diluent* AND In *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times D \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$ AND Delete *D* = dilution factor for the *Sample solution*, 2.5 In test *A*: Change The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, both relative to the internal standard, as obtained in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Assay. to: The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
FELODIPINE	IM PUR ITIES/*Organic Impurities*	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	Change **Buffer**, **Mobile phase**, **System suitability solution**, **Standard solutio n**, **Sample solution**, and **Chromatograp hic system**: Proceed as directed in the *Assay*. to: **Buffer**, **Mobile phase**, **System suitability**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution, **Standard solution**, **Sample solution**, and **Chromatographic system**: Proceed as directed in the *Assay*, and use 40 µL injection volume for the *Sensitivity solution*.
PENICILLIN G BENZATHINE INJECTABLE SUSPENSION	IDENTIFICATION	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	Change It responds to the *Identification test* under *Penicillin G Benzathine Oral Suspension*. to: Mix a portion of it with methanol to obtain a solution containing about 3000 Penicillin G Units per mL.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Apply 20 µL of this test solution and 20 µL of a Standard solution of USP Penicillin G Benzathine RS in methanol containing 2.5 mg per mL to a suitable thin-layer chromatographic plate (see *Chromatography* ?621?) coated with a 0.25-mm layer of chromatographic silica gel, and allow the spots to dry. Using an unlined developing chamber, develop the chromatogram in a solvent system consisting of a mixture of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								methanol, acetonitrile, and ammonium hydroxide (70:30:3) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, and allow to air-dry. Spray the plate uniformly with a spray reagent prepared as follows. Dissolve 20 g of tartaric acid and 1.7 g of bismuth subnitrate in 80 mL of water. Add 2.5 mL of this solution, 2.5 mL of potassium iodide solution (4 in 10), and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								10 g of tartaric acid to 50 mL of water, and mix. Examine the chromatograms: the principal spot obtained from the test solution corresponds in R_F value to that obtained from the Standard solution.
ADIPIC ACID	IM PUR ITIES/*Related Substances*	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	In *Table 2*: Change Pimelic acid 1.21 0.91 Valeric acid 1.21 0.91 to: Pimelic acid 1.21 0.91 Valeric acid 1.46 0.88
ROCURONIUM BROMIDE	CHEMICAL INFORMATION	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*USPNF 2023 Issue 3*	Change 609.68 to: 609.69
ZINC UNDECY LENATE	ASSAY/ *Procedure*	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	In *Solution A*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well. to: 0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of 0.5 N hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well.
PENICILLIN G BENZATHINE	IDENTIFICATION	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	In *Test A*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AND PENICILLIN G PROCAINE INJECTABLE SUSPENSION								It responds to the *Identification* test under *Penicillin G Benzathine Oral Suspension*: the spot obtained from the test solution, corresponding in R_F value to that obtained from the Standard solution, is completely resolved from a second spot, produced by penicillin G procaine. to: Mix a portion of it with methanol to obtain a solution containing about 3000 Penicillin G Units per mL.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Apply 20 µL of this test solution and 20 µL of a Standard solution of USP Penicillin G Benzathine RS in methanol containing 2.5 mg per mL to a suitable thin-layer chromatographic plate (see *Chromatography* ?621?) coated with a 0.25-mm layer of chromatographic silica gel, and allow the spots to dry. Using an unlined developing chamber, develop the chromatogram in a solvent system consisting of a mixture of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								methanol, acetonitrile, and ammonium hydroxide (70:30:3) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, and allow to air-dry. Spray the plate uniformly with a spray reagent prepared as follows. Dissolve 20 g of tartaric acid and 1.7 g of bismuth subnitrate in 80 mL of water. Add 2.5 mL of this solution, 2.5 mL of potassium iodide solution (4 in 10), and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								10 g of tartaric acid to 50 mL of water, and mix. Examine the chromatograms: the principal spot obtained from the test solution corresponds in R_F value to that obtained from the Standard solution. The spot obtained from the test solution, corresponding in R_F value to that obtained from the Standard solution, is completely resolved from a second spot, produced by penicillin G procaine.
POTASSIUM CITRATE EXTE	PERFORMANCE	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	In *Test 6*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NDED-RELEASE TABLETS	TESTS/ *Dissolution <711>*							**Times**: 0.5, 1, and 4 h—for strengths 540 and 1080 mg as potassium citrate monohydrate; 0.5, 1, and 6 h—for strength 1620 mg as potassium citrate monohydrate. to: **Times**: 0.5, 1, and 4 h—for strength 540 mg as potassium citrate monohydrate; 0.5, 1, and 6 h—for strengths 1080 and 1620 mg as potassium citrate monohydrate.
CALCIUM L-5-METHYLTETRAHYDROFOLA	IM PURITIES/*Related*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change C_S =

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TE	*Compounds*							concentration of USP Calcium D L-5-Methyltetra hydrofolate RS in the *Standard solution* (mg/mL) to: C_S = concentration of USP Calcium D, L-5-Methyltetra hydrofolate RS in the *Standard solution* (mg/mL)
SITAGLIPTIN PHOSPHATE	CHEMICAL INFORMATION	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	Change 523.32 to: 523.33 AND Change (3*R*)-3-Amino-1-[3-(trifluoromethyl)- 5,6-dihydro[1,2, 4]t riazo lo[4,3-*a*]pyr azin-7(8*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-yl-4-(2,4,5-trifluorophenyl)butan-1-one phosphate monohydrate to: (3*R*)-3-Amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one phosphate monohydrate
DOFETILIDE	CHEMICAL INFORMATION	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	Change ?-[(*p*-Methanesulfonamidophenethyl)methylamino]methane sulfono-*p*-phenetidide to: *N*-{4-[2-(Methyl{2-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CALCIUM UNDECYLENATE	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	[4-(methylsulfonamido)phenoxy]ethyl}amino)ethyl]phenyl}methanesulfonamide In *Solution A*: Change 0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well. to: 0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of 0.5 N hydrochloric acid VS to a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								500-mL volumetric flask, dilute with water to volume, and mix well.
CALCIUM L-5-METHYLTETRAHYDROFOLATE	IDENTIFICATION	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *A. Spectroscopic Identification Tests <197>, Infrared Spectroscopy: 197K*: Change USP Calcium D L-5-Methyltetrahydrofolate RS to: USP Calcium D, L-5-Methyltetrahydrofolate RS
TETRACYCLINE HYDROCHLORIDE	SPECIFIC TESTS/ *Bacterial Endotoxins Test <85>*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	Change Where the label states tetracycline hydrochloride must be subjected to further processing during the preparation of injectable

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dosage forms, the level of bacterial endotoxins are such that the requirement under the relevant dosage form monograph(s) in which tetracycline hydrochloride is used can be met. to: Where the label states Tetracycline Hydrochloride must be subjected to further processing during the preparation of injectable dosage forms, the level of bacterial endotoxins are

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								such that the requirement under the relevant dosage form monograph(s) in which Tetracycline Hydrochloride is used can be met.
DOXORUBICIN HYDROCHLORIDE INJECTION	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
DIAZOXIDE	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In footnote a in *Table 2*: Change 7-Chl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oro-2*H*-benzothiadiazin-3(4*H*)-one 1,1-dioxide. to: 7-Chloro-2*H*-1,2,4-benzothiadiazin-3(4*H*)-one 1,1-dioxide.
CALCIUM L-5-METHYLTETRAHYDROFOLATE	IMPURITIES/ *Enantiomeric Purity*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Standard solution*: Change USP Calcium D L-5-Methyltetrahydrofolate RS to: USP Calcium D, L-5-Methyltetrahydrofolate RS
DOXORUBICIN HYDROCHLORIDE FOR INJECTION	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								P = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
PRIMIDONE TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Oct-2022	1-Dec-2022	*NA*	*NA*	In *Sample solution*: Change 0.05 mg/mL of primidone from the *Standard stock solution* in *Diluent* to: 0.05 mg/mL of primidone from the *Sample stock solution* in *Diluent*
ANETHOLE	DEFINITION	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	Change (*E*)-1-methyl-4-(1-propenyl) benzene to: (*E*)-1-methoxy-4-(1-propenyl) benzene

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CALCIUM L-5-METHYLTETRAHYDROFOLATE	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *System suitability solution*: Change USP Calcium D L-5-Methyltetrahydrofolate RS to: USP Calcium D, L-5-Methyltetrahydrofolate RS AND In *Standard solution*: Change USP Calcium D L-5-Methyltetrahydrofolate RS to: USP Calcium D, L-5-Methyltetrahydrofolate RS AND In *System suitability/Samples*: Change USP Calcium D L-5-Methyltetrahydrofolate RS to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								USP Calcium D, L-5-Methyltetra hydrofolate RS AND In *Analysis*: Change C_S = concentration of USP Calcium D L-5-Methyltetra hydrofolate RS in the *Standard solution* (mg/mL) to: C_S = concentration of USP Calcium D, L-5-Methyltetra hydrofolate RS in the *Standard solution* (mg/mL)
TETRACYCLINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*Labeling*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	Change Where tetracycline hydrochloride must be sterile or subjected to further processing

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								during the preparation of injectable dosage forms to ensure acceptable levels of bacterial endotoxins, it is so labeled. to: Where Tetracycline Hydrochloride must be sterile or subjected to further processing during the preparation of injectable dosage forms to ensure acceptable levels of bacterial endotoxins, it is so labeled.
DOXORUBICIN HYDROCHLORIDE INJECTION	IM PUR ITIES/*Organic*	*USPNF 2022 Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change *P* = potency of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Impurities							doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
DOXAZOSIN MESYLATE	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change C_S = concentration of the corresponding USP Doxazosin Related Compound RS or USP Doxazosin Mesylate RS (for calculating unspecified impurities) in the *Standard solution* (mg/mL)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: C_S = concentration of the corresponding USP Reference Standard or USP Doxazosin Mesylate RS (for calculating unspecified impurities) in the *Standard solution* (mg/mL)
CALCIUM L-5-METHYLTETRAHYDROFOLATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	Change USP Calcium D L-5-Methyltetrahydrofolate RS to: USP Calcium D, L-5-Methyltetrahydrofolate RS
DOXORUBICIN HYDROCHLORIDE FOR INJECTION	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
ENZACAMENE	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Oct-2022	1-Dec-2022	*NA*	*NA*	In *Analysis*: Change C_U = concentration of enzacamene in the *Sample solution* (mg/mL) to: C_U = concentration of Enzacamene in the *Sample solution* (mg/mL)
NALOXONE HYDROCHLORIDE	IMPURITIES	*USPNF Online*	Online	28-Oct-2022	1-Dec-2022	*NA*	*NA*	In *Limit of Naloxone Related Compound D*: Delete **Sensitivity solution**: 1.25 µg/mL of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Naloxone Related Compound D RS in 0.1 N hydrochloric acid AND In *System suitability*/*Samples*: Delete *Sensitivity solution*, AND In *System suitability*/*Suitability requirements*: Delete **Signal-to-noise ratio**: NLT 10, *Sensitivity solution*
N-Benzoyl-L-arginine Ethyl Ester Hydrochloride	REAGENT SPECIFICATIONS	*USPNF Online*	Online	30-Sep-2022	1-Dec-2022	*NA*	*NA*	Change Crystallized Trypsin (USP Monograph). to: Trypsin (USP Monograph).
SODIUM	IM	*USPNF Online*	Online	30-Sep-2022	1-Oct-2022	*NA*	*NA*	In *Buffer*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PICOSULFATE	PURITIES/*Organic Impurities*							Change cetylrimethylammonium bromide, to: cetyltrimethylammonium bromide,
LANSOPRAZOLE DELAYED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	30-Sep-2022	1-Oct-2022	*NA*	*NA*	Delete **Blank**: Methanol and *Diluent* (1:9)
TERAZOSIN CAPSULES	ASSAY/ *Procedure*	*USPNF Online*	Online	30-Sep-2022	1-Oct-2022	*NA*	*NA*	In *Hydrochloric acid solution*: Change 0.1 N methanolic hydrochloric acid to: 0.01 N methanolic hydrochloric acid

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2

- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »